Not yet investigated
What we have so far
An enzyme carried on LDL that marks plaque inflammation. The drug built to block it failed twice in large trials, which is its own lesson.
This star is on the map because the show intends to take the question apart properly — the trials, how it is actually tested, whether the thing sold is the thing studied. That work is not done yet, and nothing here should be read as a conclusion. When the investigation is published it will appear on this page.